Safety and efficacy of topical finasteride nanoemulgel 0.25% in the treatment of mild to moderate androgenetic alopecia

Safety and efficacy of topical finasteride nanoemulgel 0.25% in the treatment of mild to moderate androgenetic alopecia on male and female pattern

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

IRCT

Registry ID

IRCT20190210042676N22

Enrollment

Registered

2022-05-13

Start date

2022-05-22

Completion date

Unknown

Last updated

2022-05-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

hair loss. Nonscarring hair loss, unspecified

Interventions

Intervention group: Treatment with topical finasteride nanoemulgel 0.25% in scalp area, once in a day for 24 weeks. This emulgel is prepared by high-speed homogenization method with nanoemulsion conta

Eligibility

Sex/Gender

All

Age

20 Years to 50 Years

Inclusion criteria

Inclusion criteria: Male or female aged 20-50 years Hair Loss Status II, III, IV Based on Norwood Scale for men Hair Loss Status I,II Based on Ludwick Scale for women General health Voluntary participation and signing written informed consent

Exclusion criteria

Exclusion criteria: Chronic active scalp disease other than hair loss Using any prescribed drug or over-the-counter(OTC) for hair loss within the past 3 months Women with abnormal hormonal tests Women with Polycystic ovary(PCO) pregnancy or lactating women

Design outcomes

Primary

Measure	Time frame
Hair count changes. Timepoint: Before intervention, 2, 4 and 6 months after the start of treatment. Method of measurement: Trichoscopy by Fotofinder.	—

Secondary

Measure	Time frame
Changes in the ratio of anagen to telogen hair. Timepoint: Before intervention, 2, 4 and 6 months after the start of treatment. Method of measurement: Trichoscopy by Fotofinder.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactAniseh Samadi

Tehran University of Medical Sciences

aniseh_samadi@yahoo.com+98 21 8896 0880

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026